高危非肌层浸润性膀胱癌膀胱镜监测强度的变化
该研究基于真实世界临床数据对10万名70岁确诊的高危非肌层浸润性膀胱癌患者进行微模拟,比较五种指南推荐的监测方案及两种假设的监测强度升级与降级方案。结果显示,监测强度升级相比降级仅使10年肌层浸润性膀胱癌累积发生率从11.9%降至10.5%,癌症特异性生存率从94.9%升至95.4%,总生存率从69.6%升至69.9%,但增量成本效果比超过每质量调整生命年336 000美元。作者认为中度监测降级与10年总生存率无显著变化相关,且相比高强度监测方案具有成本效益。
要点
- 指南推荐的监测方案10年肌层浸润性膀胱癌累积发生率为11.0%至11.6%,癌症特异性生存率95.0%至95.2%,总生存率69.7%至69.8%。
- 监测强度升级相比降级,10年肌层浸润性膀胱癌累积发生率10.5% vs 11.9%,癌症特异性生存率95.4% vs 94.9%,总生存率69.9% vs 69.6%。
- 相比监测强度降级,较高强度方案每增加一个质量调整生命年的增量成本≥336 000美元,远超常规支付意愿阈值。
核心结论
- 在针对新诊断高危非肌层浸润性膀胱癌患者的微模拟中,中度监测降级似乎与10年总生存率无显著变化相关,且相比高强度监测方案具有成本效益。
- 这些结果提示,中度监测降级可降低医疗费用而不影响许多患者的预期寿命。
研究设计与样本
- 研究采用真实世界临床数据驱动的微模拟,模拟一个假设队列,包含100 000名在70岁时诊断的高危非肌层浸润性膀胱癌患者。
- 队列模拟接受五种指南推荐的替代监测方案,以及两种假设方案——监测强度升级和降级,其监测强度分别适度高于和低于指南推荐方案。
- 评估指标包括10年肌层浸润性膀胱癌累积发生率、癌症特异性生存率、总生存率,以及从美国医疗支付方角度的成本效益。
主要发现
- 指南推荐的监测方案导致估计的10年肌层浸润性膀胱癌累积发生率为11.0%至11.6%,癌症特异性生存率为95.0%至95.2%,总生存率为69.7%至69.8%。
- 监测强度升级导致10年肌层浸润性膀胱癌累积发生率为10.5%(95%CI 10.3-10.7%),癌症特异性生存率为95.4%(95%CI 95.2-95.5%),总生存率为69.9%(95%CI 69.6-70.1%);而监测强度降级分别为11.9%(95%CI 11.7-12.1%)、94.9%(95%CI 94.8-95.1%)和69.6%(95%CI 69.3-69.9%)。
- 通过增加监测强度,10年内预防一例额外肌层浸润性膀胱癌进展的需治疗人数≥80,避免一例额外癌症相关死亡的需治疗人数≥257。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the clinical, economic, and health utility outcomes associated with alternative cystoscopic surveillance regimens for high-risk non-muscle-invasive bladder cancer (HRNMIBC). PATIENTS AND METHODS: We performed real-world clinical data-driven microsimulations of a hypothetical cohort of 100 000 patients diagnosed with HRNMIBC at age 70 years. The cohort was simulated to undergo alternative surveillance regimens recommended by five guidelines, and two hypothetical regimens-surveillance intensity escalation and de-escalation-which had a surveillance intensity moderately higher and lower, respectively, than the guideline-recommended regimens. We evaluated the 10-year cumulative incidence of muscle-invasive bladder cancer (MIBC), cancer-specific survival (CSS), overall survival (OS), and cost-effectiveness from a United States healthcare payer perspective. RESULTS: The guideline-recommended surveillance regimens led to an estimated 10-year cumulative incidence of MIBC ranging from 11.0% to 11.6%, CSS 95.0% to 95.2%, and OS 69.7% to 69.8%. Surveillance intensity escalation resulted in a 10-year cumulative incidence of MIBC of 10.5% (95% confidence interval [CI] 10.3-10.7%), CSS of 95.4% (95% CI 95.2-95.5%), and OS of 69.9% (95% CI 69.6-70.1%), vs 11.9% (95% CI 11.7-12.1%), 94.9% (95% CI 94.8-95.1%), and 69.6% (95% CI 69.3-69.9%), respectively, from surveillance intensity de-escalation. By increasing surveillance intensity, the number-needed-to-treat to prevent one additional MIBC progression over 10 years was ≥80, and ≥257 to avoid one additional cancer-related mortality. Compared to surveillance intensity de-escalation, higher-intensity regimens incurred an incremental cost of ≥$336 000 per incremental quality-adjusted life year gained, which well exceeded conventional willingness-to-pay thresholds, ≥$686 000 per additional MIBC progression prevented, and ≥$2.2 million per additional cancer-related mortality avoided. CONCLUSION: In microsimulations testing a wide range of cystoscopic surveillance intensity for patients newly diagnosed with HRNMIBC, moderate surveillance de-escalation appears associated with an insignificant change in 10-year OS and furthermore is cost-effective vs higher-intensity surveillance regimens. These results suggest that moderate surveillance de-escalation can reduce costs of care without compromising life expectancy for many patients.
引用
- Su ZT, Florissi IS, Mahon KM, et al. Varying the intensity of cystoscopic surveillance for high-risk non-muscle-invasive bladder cancer. BJU Int. 2024. PMID: 39210627. doi:10.1111/bju.16521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。